Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» InterMune
InterMune
Lax Approval Requirements Yield Blockbusters That Don’t Work
Lax Approval Requirements Yield Blockbusters That Don’t Work
Xconomy
FDA
drug approvals
conditional approvals
InterMune
Actimmune
IPF
Flag link:
Pharma's top 10 M&A deals of 2014
Pharma's top 10 M&A deals of 2014
Fierce Pharma
M&A
Actavis
Allergan
Forest Labs
GSK
Novartis
Bayer
Merck
Cubist Pharma
Roche
InterMune
Mylan Labs
Abbott Labs
Questcor
Mallinckrodt
Eli Lilly
Sun Pharma
Ranbaxy
Flag link:
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
The Nominees for Best Biotechnology Co. CEO of 2014 Are...
TheStreet.com
biotech
EXACT Sciences
Idenix
Prosensa
Agios Pharmaceuticals
Bluebird Bio
InterMune
Flag link:
Roche launches US$5.75bn bond to back InterMune deal -lead
Roche launches US$5.75bn bond to back InterMune deal -lead
Yahoo/Reuters
Roche
InterMune
M&A
Flag link:
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action
InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action
Yahoo/PR Newswire
InterMune
Flag link:
Roche CEO Schwan took a hands-on approach negotiating $8.3B InterMune buyout
Roche CEO Schwan took a hands-on approach negotiating $8.3B InterMune buyout
Fierce Biotech
Roche
Pharma CEOs
Severin Schwan
M&A
InterMune
Flag link:
Roche, InterMune a Strategic Play in Midst of Inversions
Roche, InterMune a Strategic Play in Midst of Inversions
TheStreet.com
Roche
InterMune
tax inversions
M&A
Flag link:
There's still hunger for 'blockbuster' biotech deals
There's still hunger for 'blockbuster' biotech deals
CNBC
biotech
Roche
InterMune
M&A
Flag link:
Roche And InterMune Beckon Pharma's Summer of Discontent
Roche And InterMune Beckon Pharma's Summer of Discontent
Forbes
Roche
InterMune
M&A
Flag link:
Roche Said to Have Decided Against Bid for Rest of Chugai
Roche Said to Have Decided Against Bid for Rest of Chugai
Bloomberg
Roche
Chugai
M&A
InterMune
Flag link:
Roche CEO On Intermune Deal: 'This Is A Growth Story'
Roche CEO On Intermune Deal: 'This Is A Growth Story'
Forbes
Pharma CEOs
InterMune
Roche
M&A
Severin Schwan
Flag link:
Roche to buy U.S. biotech firm InterMune for $8.3 billion
Roche to buy U.S. biotech firm InterMune for $8.3 billion
Yahoo/Reuters
Roche
InterMune
M&A
Flag link:
Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths
Roche's InterMune Acquisition Underscores How It And Pfizer Are On Different M&A Paths
Forbes
Roche
InterMune
Pfizer
M&A
Flag link:
Most Popular News Headlines For Wednesday, August 13 2014
Most Popular News Headlines For Wednesday, August 13 2014
CP Wire
Pfizer
Bristol-Myers Squibb
Eliquis
Belsomra
insomnia
Kyprolis
Aranesp
Amgen
InterMune
Sanofi
Roche
Flag link:
Most popular news headlines for Wednesday, August 13 2014
Pfizer
Bristol-Myers Squibb
Eliquis
Belsomra
insomnia
Kyprolis
Aranesp
Amgen
InterMune
Sanofi
Roche
Flag link:
InterMune buyout rumors resurface, with Roche, Sanofi on the short list
InterMune buyout rumors resurface, with Roche, Sanofi on the short list
Fierce Biotech
InterMune
Roche
Sanofi
M&A
Flag link:
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
4 Biotech Stocks Worth A Look Ahead Of FDA Approvals
Yahoo/Benzinga
FDA
drug approvals
Acadia
Alexion
InterMune
Merrimack Pharmaceuticals
Soliris
pimavanserin
MM-398
Esbriet
Flag link:
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher
24/7 Wall St
Alexion
InterMune
FDA
Acadia
Kythera
Intercept Pharmaceuticals
Merrimack Pharmaceuticals
Relypsa
MM-398
patiromer
Esbriet
ATX-101
Soliris
Flint
pimavanserin
Flag link:
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
Seeking Alpha
InterMune
Esbriet
Actelion
Gilead Sciences
Flag link:
After Idenix: The Next Four Biotech Buyout Candidates
After Idenix: The Next Four Biotech Buyout Candidates
24/7 Wall St
Idenix
M&A
Merck
Biocryst
Dynavax
InterMune
Vertex Pharmaceuticals
Flag link:
Pages
1
2
3
4
5
6
7
8
next ›
last »